Core Viewpoint - The company reported positive results from its ASC30 oral small molecule GLP-1 receptor agonist in a clinical trial, highlighting its efficacy and safety for obesity treatment [1] Group 1: Clinical Trial Details - The ASC30 study is a Phase Ib multi-dose escalation (MAD) trial conducted in the United States, focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy in obese subjects with a BMI of 30-40 kg/m² [1] - The trial is randomized, double-blind, and placebo-controlled, ensuring robust data collection and analysis [1] Group 2: Future Expectations - The company anticipates reporting the top-line results of the 13-week Phase IIa study of ASC30 in the fourth quarter of this year [1] - The CEO emphasized the strong research and development capabilities of the company, aiming to provide differentiated treatment options for obesity [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 歌禮在第61屆歐洲糖尿病研究協會(EASD) 年會上報告其ASC30口服小分子GLP-1R激動劑 28天多劑量遞增研究隊列1和隊列2的結果 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣布，在2025年9月16日在奧地利維也納舉 行的第61屆歐洲糖尿病研究協會(EASD)年會上的簡短口頭討論專場會議A中報告 了其ASC30口服小分子GLP-1受體(GLP-1R)激動劑28天多劑量遞增(MAD)研究 (NCT06680440)隊列1和隊列2的結果。 該Ib期MAD研究是一項在美國開展的隨機、雙盲、安慰劑對照的研究，旨在評估 ASC30每日一次 ...

Market Overview - A-shares experienced a rebound in the afternoon, with the Sci-Tech 50 index showing strong performance, rising over 2% during the session [1] - The Shanghai Composite Index closed slightly up by 0.04% at 3861.87 points, while the Shenzhen Component rose by 0.45% to 13063.97 points, and the ChiNext Index increased by 0.68% to 3087.04 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 23.673 billion yuan, an increase of 639 million yuan compared to the previous day [1] Sector Performance - The logistics sector saw significant gains, with companies like New Ning Logistics, Jushen Co., and Yiatong hitting the daily limit [1] - The automotive supply chain stocks were active, with Hengshuai Co. and Junsheng Electronics also reaching the daily limit [1] - The robotics concept stocks surged, with Anpeilong and Hanwei Technology hitting the daily limit and achieving new highs [1][3] Robotics Sector Developments - The robotics concept saw renewed activity, with several companies including Hengshuai Co., Anpeilong, Hongchang Technology, and Hanwei Technology all hitting the 20% limit up [3] - Yushu Technology announced the open-source UnifoLM-WMA-0 architecture, aimed at advancing the global embodied intelligence industry [4] - Elon Musk mentioned the progress of Tesla's Optimus Gen3 at the All-In Summit, highlighting its human-like dexterity and plans for mass production [5] Company-Specific News - The stock of Yaojie Ankang experienced a dramatic drop, closing down 53.7% after previously surging over 60% during the day [6][7] - Yaojie Ankang's board confirmed that they were unaware of the reasons behind the stock price fluctuations, stating that the company's operations and financial status remain stable [9] - The company recently received clinical approval for its core product, Tinengotinib, for treating specific types of breast cancer [9]

Market Overview - A-shares saw a rebound in the afternoon with the Sci-Tech 50 index performing strongly, rising over 2% during the session [1] - The Shanghai Composite Index closed slightly up by 0.04% at 3861.87 points, while the Shenzhen Component rose by 0.45% to 13063.97 points, and the ChiNext Index increased by 0.68% to 3087.04 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 236.73 billion yuan, an increase of 63.9 billion yuan from the previous day [1] Sector Performance - The logistics sector saw significant gains, with stocks like New Ning Logistics, Jushen Co., and Yiatong hitting the daily limit [1] - The automotive supply chain stocks were active, with Hengshuai Co. and Junsheng Electronics also reaching the daily limit [1] - The robotics sector experienced a resurgence, with stocks such as Anpeilong and Hanwei Technology hitting new highs [1][2] Robotics Sector Developments - The robotics concept stocks were notably active, with several companies including Hengshuai Co., Anpeilong, Hongchang Technology, and Hanwei Technology all hitting the daily limit of 20% [2] - Yushu Technology announced the open-source UnifoLM-WMA-0 architecture, aimed at advancing the global embodied intelligence industry [2] Tesla's Robotics Progress - Elon Musk mentioned at the All-In Summit that Tesla is completing the design of the Optimus Gen3, which will feature human-like dexterity and AI capabilities [4] - The supply chain related to the dexterous hand of the Optimus Gen3 is expected to be a key focus area, with potential collaborations in the pipeline [4] Pharmaceutical Sector Update - The stock of Yaojie Ankang experienced extreme volatility, initially surging over 60% before closing down 53.7%, with a trading range exceeding 120% [5][7] - The company announced that its core product, Tinengotinib, received clinical approval for a trial in treating specific types of breast cancer [7]

Core Viewpoint - The article discusses the dramatic rise and fall of the stock price of Yaojie Ankang, a biopharmaceutical company, highlighting its recent surge due to clinical trial approvals and the broader context of the innovative drug market in Hong Kong [3][8][17]. Company Overview - Yaojie Ankang, founded in 2014 and led by Wu Yongqian since 2016, focuses on developing small molecule therapies for cancer and other diseases [4][12][13]. - The company went public on June 23, 2023, with an initial price of 13.15 HKD, and saw its market capitalization soar to over 260 billion HKD shortly after [6][8]. Stock Performance - The stock experienced a staggering increase of up to 5000% within three months, reaching a peak price of 680 HKD, before a significant drop back to around 700 billion HKD [3][8][10]. - The surge was attributed to the announcement of clinical trial approvals for its core product, Tinegotinib, which led to substantial daily price increases [9][10]. Market Context - The article notes a broader bullish trend in the Hong Kong innovative drug sector, with many companies experiencing significant stock price increases, indicating a potential "bull market" for innovative drug companies [9][17]. - Despite the excitement, concerns are raised about the sustainability of such valuations, especially given Yaojie Ankang's lack of approved products and ongoing financial losses [8][17]. Leadership and Strategy - Wu Yongqian's background in chemistry and his leadership role in Yaojie Ankang are highlighted as key factors in the company's strategic direction and growth [12][14]. - The company has successfully raised over 1.7 billion CNY through multiple funding rounds, indicating strong investor confidence despite its current financial status [13][14]. Regional Influence - The article emphasizes the significance of Nanjing's biopharmaceutical ecosystem, which has supported Yaojie Ankang's growth through resources and infrastructure [14][16]. - Nanjing's strategic location and educational institutions contribute to a robust talent pool, fostering innovation in the biopharmaceutical sector [16].

港股创新药概念股震荡走弱，歌礼制药-B跌近8%，诺诚健华跌超6%，复星医药、中国生物制药、石四 药集团纷纷下挫。 ...

隔夜美股纳指标普联袂创新高，热门中概股多数上涨。港股三大指数高开，恒指涨0.34%，国指涨 0.25%，恒生科技指数涨0.45%。盘面上，大型科技股多数呈现上涨行情但总体波动不大，美团、快 手、腾讯、小米、网易、百度涨幅在0.7%以内，京东、阿里巴巴小幅下跌；昨日尾盘大幅拉升的生物 医药股继续强势，昨日飙涨超115%的药捷安康再度高开近15%，歌礼制药、君实生物、药明巨诺等纷 纷上涨；现货黄金逼近3690美元，续创历史新高，黄金股持续走强，中国黄金国际、灵宝黄金、招金矿 业均涨超3%，核电股、汽车股、锂电池股、海运股多数上涨。另一方面，物流股、白酒概念股、内房 股、电信股部分走低，其中，中国联通跌约1%。此外，"激光雷达第一股" 禾赛首日在港挂牌上市高开 近8%。(格隆汇） ...

Core Viewpoint - The article highlights the positive market response to the announcement by Gilead Sciences-B (01672) regarding its long-acting subcutaneous formulation ASC30 for weight management, which shows a promising 75-day apparent half-life in obese subjects, indicating potential for quarterly dosing in the future [1] Company Developments - Gilead Sciences' stock rose over 4%, reaching HKD 11.63 with a trading volume of HKD 37.09 million following the announcement [1] - The ASC30 formulation is developed using Gilead's Ultra Long-Acting Pharmaceutical (ULAP) platform, showcasing the company's innovation in drug development for obesity management [1] Clinical Trials and Future Prospects - Gilead's major shareholder has committed to a voluntary lock-up, agreeing not to sell any shares before the release of three key clinical data points: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 4% following the announcement of promising clinical data for its long-acting GLP-1R agonist ASC30, indicating potential for quarterly dosing in weight management [1] Group 1: Clinical Developments - Gilead announced that its small molecule GLP-1R agonist ASC30 has shown a 75-day apparent half-life in obese subjects, suggesting a long-term weight management solution [1] - The ASC30 formulation is developed using Gilead's Ultra Long-Acting Drug Development Platform (ULAP) [1] Group 2: Shareholder Commitments - Gilead's controlling shareholder has made a voluntary lock-up commitment, agreeing not to sell any shares before the release of three key clinical data points [1] - The three data points include: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025 [1] 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025 [1] 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1]

Macro and Strategy Research - The US labor market shows signs of weakness, with August non-farm employment data falling short of expectations and previous months' figures revised downwards, indicating a potential deterioration trend [3][4] - In Europe, the European Central Bank remains confident about future inflation and economic growth, with market expectations for a rate cut before mid-2026 dropping below 50% [4] - Domestic exports in China have declined year-on-year due to high base effects from last year, but exports to non-US regions continue to perform better, which may influence future growth [4][7] - The PPI in China is expected to show a low recovery in September, while CPI growth is significantly affected by food and energy prices [4][7] Fixed Income Research - The yield curve has steepened, with the bond market under pressure due to a strong equity market and adjustments in redemption fees affecting market sentiment [8][9] - In the primary market, the issuance of interest rate bonds totaled 74, with a net financing amount of 45.2 billion yuan, indicating a gradual decrease in supply pressure [7][9] - The central bank's actions, including potential 14-day reverse repos, will be crucial in determining the liquidity situation in the market [9] Industry Research - Chinese pharmaceutical companies showcased impressive research results at the World Lung Cancer Conference (WCLC), highlighting the strength of domestic innovation [10][12] - Hengrui Medicine has signed a licensing agreement for the HRS-1893 project and has received drug registration approval, indicating its ongoing expansion efforts [11][12] - The overall performance of the pharmaceutical and biotechnology sector has been positive, with the industry index showing a 1.76% increase, outperforming other sectors [11][12] - The upcoming China Clinical Oncology Society (CSCO) annual meeting and the European Society for Medical Oncology (ESMO) conference are expected to provide further insights into the industry's development [12]